Gladius Capital Management LP Buys New Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Gladius Capital Management LP purchased a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 513 shares of the company’s stock, valued at approximately $35,000.

A number of other large investors have also modified their holdings of PBH. Opal Wealth Advisors LLC acquired a new stake in Prestige Consumer Healthcare in the 2nd quarter worth approximately $26,000. GAMMA Investing LLC acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $25,000. EverSource Wealth Advisors LLC grew its holdings in shares of Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock valued at $33,000 after buying an additional 208 shares during the last quarter. Principal Securities Inc. acquired a new position in shares of Prestige Consumer Healthcare in the 4th quarter valued at $29,000. Finally, ORG Partners LLC purchased a new position in Prestige Consumer Healthcare in the 4th quarter worth $36,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. StockNews.com lowered Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 21st. DA Davidson reissued a “buy” rating and set a $93.00 price target on shares of Prestige Consumer Healthcare in a research report on Friday, August 9th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Prestige Consumer Healthcare in a report on Tuesday, May 21st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $98.25.

Prestige Consumer Healthcare Stock Performance

PBH stock traded down $0.14 during trading on Friday, hitting $68.55. 285,681 shares of the company traded hands, compared to its average volume of 251,517. Prestige Consumer Healthcare Inc. has a 1 year low of $56.34 and a 1 year high of $75.31. The company has a market cap of $3.41 billion, a PE ratio of 16.44, a P/E/G ratio of 1.88 and a beta of 0.49. The stock’s 50-day simple moving average is $68.48 and its 200 day simple moving average is $68.73. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.04. Prestige Consumer Healthcare had a net margin of 18.43% and a return on equity of 12.55%. The firm had revenue of $267.10 million during the quarter, compared to analyst estimates of $260.54 million. During the same period in the previous year, the firm earned $1.06 EPS. The business’s quarterly revenue was down 4.4% on a year-over-year basis. On average, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.41 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.